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Objectives: To provide clinicians with practical considerations for 
care of children with Ebola virus disease in resource-rich settings.
Data Sources: Review of the published medical literature, World 
Health Organization and government documents, and expert opinion.
Data Synthesis: There are limited data regarding Ebola virus dis-
ease in children; however, reported case-fatality proportions in 
children are high. Ebola virus may affect immune regulation and 
endothelial function differently in children than adults. Consider-
ations for care of children with Ebola virus disease are presented.
Conclusions: Ebola virus disease is a severe multisystem disease 
with high mortality in children and adults. Hospitals and clinicians 
must prepare to provide care for patients with Ebola virus disease 
before such patients present for care, with particular attention to 
rigorous infection control to limit secondary cases. Although there 
is no proven specific treatment for Ebola virus disease, meticulous 
supportive care offers patients the best chance of survival. (Pediatr 
Crit Care Med 2015; 16:97–103)
Key Words: adolescent; child; critical care; Ebola hemorrhagic 
fever; Ebola virus; Ebola virus disease; infant; sepsis
Ebola virus infection causes a severe disease characterized by multisystem involvement and high mortality. Since the first recognized epidemics of Ebola virus in 1976, the virus has 
been responsible for sporadic outbreaks in sub-Saharan Africa. In 
March 2014, the World Health Organization was notified of an 
outbreak of Ebola virus disease (EVD) in southwestern Guinea, 
subsequently attributed to Zaire ebolavirus (EBOV). This ongo-
ing outbreak likely began in Guinea in December 2013 (1) and 
constitutes the largest Ebola virus epidemic to date with further 
spread to Liberia, Sierra Leone, Nigeria, Senegal, Mali, Spain, the 
United Kingdom, and the United States through December 2014.
Most patients with EVD have been treated in very resource-
poor settings, with interventions limited to basic supportive care; 
therefore, it is difficult to estimate the potential benefit of modern 
critical care. To date, a small number of adult patients have been 
treated in the United States and several European countries. Most 
published clinical data are derived from adult patients. There is 
limited knowledge about EVD in children; however, reported 
case-fatality proportions in children are high (2, 3).
The objective of this report is to provide clinicians with 
practical considerations for care of children with EVD in 
resource-rich settings.
TRANSMISSION OF EBOLA VIRUS
The natural reservoir for Ebola viruses is believed to be fruit 
bats, with infected mammals such as duiker antelopes and 
nonhuman primates having high mortality (4–6). Ebola virus 
particles or viral RNA have been detected in skin and body 
fluids of humans or nonhuman primates. Ebola viruses can 
enter the body through mucosal surfaces, skin breaks, or par-
enteral introduction and appear to initially infect monocytes, 
macrophages, and dendritic cells, which then disseminate the 
infection (7). Direct contact with infected animals can result in 
zoonotic transmission with subsequent spread among humans 
who had direct contact with blood or bodily fluids of infected 
persons. To date, five species of Ebola virus have been identified 
(Zaire, Sudan, Bundibugyo, Reston, and  Taï Forest) with vari-
able virulence; case-fatality proportions during outbreaks for 
EBOV infection range from 59% to 88% (8, 9), whereas there 
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are no known fatalities from Taï Forest ebolavirus infection, 
and Reston ebolavirus is not known to cause human disease.
PATHOPHYSIOLOGY OF EVD
Ebola virus has tropism for multiple tissues, including the liver 
and adrenal gland, causing hepatocellular and adrenocortical 
necrosis (7). In addition, infection triggers a dysregulated immune 
response that includes expression of several inflammatory medi-
ators and inhibition of type I interferon response (10–12). Recov-
ery from ebolavirus infection is associated with a well-regulated 
inflammatory response characterized by early Ebola-specific IgM 
and IgG production; in contrast, fatal cases are associated with an 
impaired response characterized by increased expression of sev-
eral proinflammatory cytokines, lymphocyte apoptosis, marked 
CD8(+) lymphopenia, and lack of neutralizing antibody produc-
tion (13–16). Fatal cases are also associated with high levels of 
ferritin, nitric oxide, and thrombomodulin, and higher levels of 
viremia are associated with elevated tissue factor and tissue plas-
minogen activator (13, 16, 17). Immune dysregulation has led to 
concern about bacterial superinfection (18).
Ebola virus may affect immune regulation and endothelial 
function differently in children than in adults, and markers asso-
ciated with survival differ between children and adults. Children 
infected with Sudan ebolavirus have greater elevation of interleu-
kin (IL)-10 and the chemokine regulated on activation, normal 
T-cell expressed and secreted (RANTES) marker. Fatal Sudan 
ebolavirus cases in childhood were associated with higher IL-10 
and lower RANTES levels than children who survived, while lev-
els of IL-10 and RANTES had no association with outcomes in 
adults (2). Children also had higher levels of several markers of 
endothelial overactivation, and elevations in these markers were 
associated with fatal cases in children but not in adults (2). This 
combination of immune dysregulation and endothelial damage 
shares several features with severe sepsis (19).
CLINICAL FEATURES OF EVD
Although EVD is classically divided into early, late, and ter-
minal or recovery phases, considerable overlap between these 
phases may occur. After an incubation period of 2–21 days 
(mean, 11 d), an acute febrile illness develops in patients; 
nonspecific signs and symptoms of this early phase of disease 
commonly include fever, headache, chills, malaise, myalgias, 
asthenia, vomiting, and diarrhea (3, 7, 20).
Diarrhea can be profuse and may mimic cholera. Hiccups, 
conjunctivitis, and pharyngeal erythema may also develop in 
patients, and a nonpruritic maculopapular rash on the face and 
upper body may be present during early or late phases of the 
disease (7, 18). Early laboratory abnormalities are not specific to 
Ebola and can include leukopenia, lymphopenia, thrombocyto-
penia, serum aminotransferase elevation, hyperlipasemia, hyper-
proteinemia, elevated prothrombin and partial thromboplastin 
times, fibrin split products, and elevated creatinine kinase (7, 21).
Patients with severe disease may develop shock from hypo-
volemia or sepsis, multiple organ failure, and disseminated 
intravascular coagulation; one patient with fatal disease cared 
for in a tertiary care center developed significant left ventricular 
systolic dysfunction (21). Fewer than half of patients develop 
hemorrhagic manifestations, which are often in the gastroin-
testinal tract and may be life threatening (3, 7, 21). Late neuro-
logic sequelae include confusion, delirium, seizures, and coma. 
Patients with fatal disease typically die between day 6 and 16 of 
symptoms from multisystem failure, while nonfatal cases show 
improvement by days 6–11 (11). Viral load has been reported 
to be substantially higher in fatal cases compared with survi-
vors (17, 22), although this difference may be less pronounced 
in children (2). In surviving patients, there is a prolonged con-
valescent period lasting up to 8 weeks (23), characterized by 
arthralgia, myalgia, abdominal pain, fatigue, and weakness (18, 
24). Ebola virus has been cultured from the breast milk of an 
infected patient at illness day 15 (25). The duration of infec-
tivity after resolution of viremia for other bodily fluids is not 
completely understood, but infectious virus has been recovered 
from survivor semen up to 82 days after symptom onset (26).
CARE OF CHILDREN WITH EVD
Diagnosis of EVD
Since early identification of potential Ebola cases is essential 
for implementing proper infection control measures and the 
early symptoms of EVD are nonspecific, clinicians should 
maintain a high index of suspicion for patients with both clini-
cal findings consistent with EVD (fever and symptoms such 
as headache, myalgia, abdominal pain, vomiting, diarrhea, and 
hemorrhage) and an epidemiologic risk factor within 21 days 
before symptoms onset. Such risk factors include having been 
in a country with widespread ebolavirus transmission or hav-
ing contact with a symptomatic person with EVD (27, 28).
Suspected cases of EVD should be reported to public health 
officials immediately. National public health agencies can pro-
vide guidance regarding diagnosis and infection control (29, 
30), as well as the level-4 biosafety containment laboratories 
required for safely diagnosing infection with high-risk organ-
isms such as ebolavirus.
The standard method to identify acute ebolavirus infection 
is by real-time reverse transcription-polymerase chain reaction 
testing of blood specimens (22). Other methods such as antigen-
detection enzyme-linked immunosorbent assay (ELISA) have 
been used in the past. Antibodies to Ebola virus may be detected 
using direct IgG and IgM ELISAs or IgM capture ELISA starting 
2 days after symptom onset, although patients with fatal disease 
may not develop detectable antibody responses (7).
Even during Ebola outbreaks, the likelihood of EVD in a 
febrile returned traveler is generally much lower than the likeli-
hood of more common imported febrile illnesses. In particular, 
malaria is endemic in all regions where Ebola has been identi-
fied and remains the most likely diagnosis in febrile patients 
from these regions. Delay in the diagnosis and treatment of 
malaria can lead to severe or lethal disease in a short period of 
time. Thus, urgent malaria testing should be performed in all 
children suspected of having EVD (Table 1).
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Infection Control
As with any emerging infectious illness, appropriate hospital 
infection control for Ebola virus is essential. Institutions should 
plan for the care of patients with emerging infectious illnesses 
before potentially infected patients present for care (29, 31); les-
sons and preparedness protocols from institutions that have cared 
for patients with EVD can provide practical guidance (32, 33). 
Hospitals should train clinical staff to identify signs and symp-
toms of EVD and ensure that emergency department screen-
ing includes questions regarding travel within 21 days from an 
affected country and possible exposure to Ebola virus for patients 
with symptoms compatible with EVD (29, 31, 34). Potential Ebola 
cases should be isolated immediately. Risk of Ebola virus trans-
mission to healthcare workers in resource-rich settings is expected 
to be much lower than in African field hospitals, where inadequate 
medical supplies, no running water, and no floors likely contrib-
ute to greater exposure to Ebola virus (21, 35). However, due to 
the high case fatality of EVD, lack of proven antiviral therapy, 
and healthcare worker infection in Spain and the United States, 
meticulous attention must be paid to infection control practices.
Early planning for care of patients with EVD includes taking 
inventory of existing resources and identifying potential areas for 
managing highly infectious patients. Important factors to con-
sider include the ability to provide negative pressure isolation as 
aerosol-generating procedures may be necessary, the presence of 
a private bathroom, the ability to restrict access to the room, suf-
ficient space to don and remove personal protective equipment 
safely, the ability to perform laboratory studies while minimizing 
healthcare provider exposure risk, and the ability to provide criti-
cal care if necessary without having to move the patient. Hospitals 
should consider initially admitting children with suspected EVD 
to the PICU even if they do not otherwise meet PICU admission 
criteria. Admitting patients with EVD to the more controlled and 
highly monitored PICU environment may allow more effective 
limitation of foot traffic, decrease the number of staff that must 
be educated in proper infection control measures, facilitate lower 
nurse-to-patient ratios to ensure that infection control measures 
are strictly followed, and minimize risky in-hospital transfers if 
patients deteriorate. Alternatively, hospitals may consider estab-
lishing a geographically separate Ebola treatment unit staffed by 
PICU nurses and physicians, as this may further limit potential 
exposure of other patients and healthcare workers.
Table 2 describes recommended infection control measures 
for patients with EVD. Guidelines from national public health 
agencies have changed with increased experience treating EVD 
in resource-rich settings and may continue to evolve. Regardless 
of the equipment chosen, staff must be thoroughly trained and 
meticulously monitored in the appropriate use of personal pro-
tective equipment, especially its removal (36). To decrease expo-
sure risk, only essential staff should participate in the care of 
patients with EVD. Given the profound importance of limiting 
secondary cases, children with confirmed EVD may need to be 
separated from their caregivers. Such separation may cause sig-
nificant emotional distress, which can be somewhat mitigated by 
frequent videoconferencing and additional psychological support.
To decrease opportunities for healthcare personnel exposure to 
Ebola virus, phlebotomy, procedures, laboratory testing, and the 
use of needles and sharps should be minimized as much as pos-
sible (31, 37, 38). Strict adherence to recommendations for body 
fluid specimen collection, transport, and testing (39), as well as for 
environmental infection control (40), is advisable. Hospital labora-
tories should be notified as early as possible of the need to perform 
laboratory testing for a patient suspected of having EVD so that 
appropriate packaging and transport can be ensured. Specimens 
should not be sent by pneumatic tube systems. Hospitals may 
consider using dedicated laboratory equipment for patients 
with suspected EVD and keeping this equipment at the bedside 
TABLE 1. Care of Patients With Ebola 
Virus Disease: Summary of Key Pediatric 
Considerations
Advance planning
  Institutions should plan and practice for the care of 
children with suspected EVD before such patients 
present for care
Diagnosis
  Urgent malaria testing should be performed in children 
suspected of having EVD
  Notify local public health officials immediately regarding 
suspected cases of EVD
Patient placement and infection control
  If transport can be safely undertaken, patients may benefit 
from early transfer to high-volume pediatric centers or 
biocontainment units
  Consider initial admission to PICU or an Ebola treatment 
unit led by PICU providers even for patients not yet 
critically ill
  Meticulous attention to infection control is essential to 
limiting secondary cases
  Only essential staff should participate in the care of 
patients with suspected EVD
Ebola-specific treatment
 There are no data regarding the use of anti-Ebola virus 
treatment in children; use of experimental therapy must 
occur within an acceptable ethical framework and 
should include case reporting to facilitate assessment 
of effectiveness
Monitoring and supportive care
  Closely monitor and replace fluid and electrolyte losses
  Consider placement of central venous or peripherally 
inserted central catheters to minimize venipuncture
  Avoid emergent and high-risk procedures (such as 
extracorporeal life support), which may present an 
unacceptable risk of healthcare worker exposure
Case reporting and documentation
  Strongly consider prospective, systematic case reporting to 
increase knowledge of EVD in children
EVD = Ebola virus disease.
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to decrease potential transmission (32). The decision whether to 
transport a potentially infectious patient to a tertiary care facility 
is controversial, and risks and benefits of either approach must be 
weighed; if transport can be safely undertaken (41, 42), children 
may benefit from transport to an institution with a dedicated bio-
containment unit or greater pediatric expertise.
TABLE 2. Recommended Isolation Measures for Patients Suspected of Having Ebola 
Virus Disease, Based on U.S. and Canadian Government and World Health Organization 
Recommendations (31, 36–38, 40, 65)
Patient placement
  Patients should be placed in single-patient rooms with private bathrooms
  Consider initial placement in an airborne isolation room for any patients with suspected EVD who may need aerosol-generating 
procedures
  Consider initial placement in PICU or geographically separate Ebola treatment unit to facilitate close monitoring, limit the pool of 
healthcare providers, and avoid potentially risky transfers if patients deteriorate
  Facilities should establish separate spaces for donning and removing PPE; space where PPE is removed must be sufficiently 
large to allow ideal practices without risk of surface contamination
  Nonessential contact with the patient or body fluids should be avoided
Transmission-based precautions
  In addition to universal precautions, contact and droplet precautions should be used
  All healthcare personnel and caregivers entering the patient room must be thoroughly trained in proper technique when donning 
and removing PPE; equipment must be removed without contaminating the healthcare worker or environment
  All persons entering the patient room should wear at least:
   Respiratory protection with either:
    A fit-tested N95 filtering mask and a full face shield or
    A powered air-purifying respirator with a full face shield, helmet, or headpiece
   Single-use surgical hood that extends to shoulders and fully covers neck
   Single-use fluid resistant or impermeable gown and boot covers
   Two pairs of single-use nitrile gloves with extended cuffs
   Single-use fluid resistant or impermeable apron if patient has vomiting or diarrhea
  Institutions may consider enhanced PPE beyond national guidelines
  Hospitals should assist and monitor healthcare workers to ensure close adherence to appropriate PPE donning and removal 
procedures and practices
  Once removed, disposable PPE should be discarded in biohazard waste containers, and reusable equipment must be 
appropriately disinfected before reuse
  Hospitals should identify appropriate mechanisms to safely and legally manage and dispose waste suspected to be contaminated 
with Ebola virus
Healthcare workers with significant exposures
  Healthcare workers with skin or mucocutaneous exposure to body fluids from a patient with suspected EVD should immediately 
wash affected skin surfaces with soap and water, irrigate mucous membranes copiously, and contact appropriate institutional 
personnel to report a potential exposure
Additional measures
  Aerosol-generating procedures, such as noninvasive ventilation, intubation or extubation, and open airway suctioning, should be 
avoided unless essential and should be conducted in an airborne infection isolation room
  Facilities should maintain a log of all persons entering the patient’s room
  All visitors who have had contact with the patient before hospital admission should be actively monitored for fever and other 
possible symptoms of EVD
  Local public health officials should lead efforts to monitor people exposed to EVD
EVD = Ebola virus disease, PPE = personal protective equipment.
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Treatment of Ebola Virus Infection
There is currently no approved or available treatment with 
proven efficacy against Ebola virus infection in humans. Sev-
eral promising investigational drugs are in development with 
limited data from nonhuman primate studies. Postexposure 
prophylaxis regimens consisting of monoclonal antibodies 
against virus glycoproteins or small-interfering RNA target-
ing viral proteins have shown promising results in macaques 
(43, 44), and monoclonal antibody cocktails have demon-
strated efficacy treating nonhuman primates after develop-
ment of symptoms (45, 46). Clinicians may decide to offer 
patients treatment with an Ebola investigational therapeutic 
on a compassionate use basis as long as appropriate ethical 
criteria are met and scientifically relevant data are shared to 
establish the safety and effectiveness of the treatment (47); in 
those cases, Ebola antiviral medications may be supplied by 
manufacturers if supply is adequate (48–52) and use must be 
approved by the appropriate regulatory body (53, 54). There 
is limited experience with the use of convalescent plasma to 
treat EVD in humans (55, 56). The World Health Organiza-
tion has prioritized investigation of convalescent plasma and 
whole blood therapy for EVD and issued guidance for appro-
priate use of these products, recommending transfusion of 
10 mL/kg whole blood or plasma in children with confirmed 
EVD with standardized data collection to allow assessment 
of efficacy (57, 58). No Ebola vaccines have been approved 
for clinical use, although human safety testing of investiga-
tional vaccines has been expedited in response to the 2014 
West African Ebola virus outbreak (59). Ideally, investiga-
tional therapies for patients with EVD, including convales-
cent plasma, should be used in the context of randomized 
clinical trials.
Monitoring
Due to extremely high gastrointestinal and insensible fluid 
losses, fluid intake and output must be closely monitored. A 
nasogastric tube may be placed in patients without hemor-
rhagic manifestations. Serum electrolytes should be measured 
at least daily to avoid development of life-threatening hypo-
natremia, hypokalemia, hypocalcemia, hypomagnesemia, and 
metabolic acidosis, which may occur in patients with severe 
diarrhea. Patients should be monitored for development of 
liver failure and for renal failure or cerebral edema in severe 
cases of EVD. Coagulopathy due to disseminated intravascular 
coagulation and hepatic dysfunction can occur. Thus, clinicians 
should assess for coagulopathy and clinical bleeding. Children 
with severe sepsis or septic shock should be monitored closely 
for development of cardiac compromise, especially ventricular 
dysfunction.
Clinicians should consider early placement of a central 
venous catheter or peripherally inserted central catheter to 
decrease the risk of exposure to blood from multiple phleboto-
mies and IV catheter placements. Arterial catheters may pres-
ent unacceptably high risk of bleeding and healthcare worker 
exposure; hence, consideration of other forms of monitoring 
and access for blood sampling is advised.
Supportive Care
Patients with EVD may present with hypovolemia requiring 
aggressive initial volume resuscitation. Oral fluid replacement 
is preferred in patients who are able to drink without vomiting, 
but administration of IV fluids may be necessary. Hypovole-
mia from profound vomiting and diarrhea may be exacerbated 
by capillary leak associated with immune dysregulation, and 
ongoing significant volume resuscitation to maintain normo-
volemia may be necessary. Patients may benefit from volume 
resuscitation with balanced fluids rather than saline (60). 
Patients who develop severe sepsis or septic shock should be 
managed according to international sepsis treatment guide-
lines (61). This includes early goal–directed therapy, vaso-
pressor and inotropic support as needed, glucose control, and 
enteral nutrition as tolerated. Coagulopathy should be cor-
rected if severe or associated with significant bleeding (61). 
Given the prominence of immune dysregulation in severe and 
fatal EVD, clinicians may consider employing sepsis treatment 
guidelines in any patient with severe EVD.
Although pulmonary involvement of EVD is not common, 
respiratory failure may occur due to pulmonary edema, circula-
tory overload, or acute lung injury related to blood transfusion 
or sepsis. Noninvasive ventilation may not be advisable due to 
significant droplet dispersion and associated risk to healthcare 
workers. Furthermore, elective tracheal intubation will likely 
result in lower risk to the patient and healthcare team than urgent 
intubation in the setting of aspiration or frank respiratory fail-
ure. In addition, airway protection may be required for patients 
with severe neurologic or bleeding sequelae. Noninvasive venti-
lation and tracheal intubation are aerosol-generating procedures 
requiring airborne precautions. Patients should be intubated by 
an experienced, skilled provider in order to minimize the risk of 
airway trauma and healthcare provider exposure.
Corticosteroids should generally not be administered to 
patients with EVD. However, as EVD can cause adrenocorti-
cal infection and necrosis (7), clinicians may consider stress-
dose glucocorticoid administration in patients with persistent 
shock who require escalating or persistent vasoactive support 
or replacement mineralocorticoids in patients with inappro-
priate urine sodium losses.
Due to the risk of secondary bacterial infections and the dif-
ficulty of clinical detection in the setting of a severe systemic 
viral infection, broad-spectrum antibiotics may be admin-
istered initially for patients with manifestations of possible 
sepsis. Antipyresis, analgesia, and antiemetic treatment may 
provide symptomatic relief; nonsteroidal anti-inflammatory 
drugs should be avoided due to bleeding risk. Psychosocial 
support of children and their caregivers are essential compo-
nents of high-quality care for patients infected with highly 
virulent emerging pathogens such as Ebola virus; video con-
ferencing and other technology may facilitate such support 
without increasing risk of virus transmission.
The potential benefits of each treatment must be weighed 
against both the risks to the patient and healthcare providers. 
Testing and procedures with unclear benefit should be avoided. 
Clinicians may decide to limit the use of plasmapheresis, 
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extracorporeal life support, cardiopulmonary resuscitation in 
patients with multiple organ failure, and other high-risk pro-
cedures to situations where they show clear evidence of ben-
efit for patients with EVD. In addition, emergent procedures 
may be inadvisable given the long time required to properly 
don personal protective equipment, and loss of a controlled 
environment during emergency procedures will likely cre-
ate unacceptable risk of transmission to healthcare workers. 
Institutional bioethics experts may help guide decision mak-
ing in situations where clinicians are considering resource 
restriction or nonstandard allocation. As new data become 
available regarding the efficacy and exposure risk of such pro-
cedures in the patient with EVD, recommendations regarding 
avoiding certain procedures may evolve.
Case Reporting and Documentation
Little is known about EVD in children in resource-rich settings, 
and clinicians should strongly consider prospective, systematic 
detailed case documentation to increase our collective knowl-
edge about EVD (62). The World Health Organization and the 
International Severe Acute Respiratory and Emerging Infection 
Consortium have developed a case reporting and biological sam-
pling protocol for emerging severe respiratory pathogens, includ-
ing informed consent documents and case record forms (63, 
64); this protocol can serve as a template for efforts to efficiently 
and systematically gather information about EVD. Careful case 
reporting can improve knowledge of not only EVD and its clini-
cal manifestations but also of the effects of treatment strategies.
CONCLUSION
EVD is a severe multisystem disease with high mortality in 
children and adults. Hospitals and clinicians must prepare to 
provide care for patients with EVD before such patients pres-
ent for care, with particular attention to rigorous infection 
control in order to limit secondary cases. Although there is no 
proven specific treatment for EVD, meticulous supportive care 
offers patients the best chance of survival.
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